Free Trial
→ $0. Later: $29.97. (From Profits Run) (Ad)tc pixel Free ASBP Stock Alerts

Aspire Biopharma (ASBP) Financials

Aspire Biopharma logo
$8.41 +0.01 (+0.12%)
Closing price 03:59 PM Eastern
Extended Trading
$8.48 +0.07 (+0.89%)
As of 07:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Aspire Biopharma

Annual Income Statements for Aspire Biopharma

This table shows Aspire Biopharma's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024 2025
Period end date 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 3.34 4.46 -1.31 -24
Consolidated Net Income / (Loss)		 3.34 4.46 -1.31 -24
Net Income / (Loss) Continuing Operations		 3.34 4.46 -1.31 -24
Total Pre-Tax Income 		3.34 4.46 -1.31 -24
Total Operating Income		 -0.98 -1.34 -1.21 -19
Total Gross Profit		 0.00 0.00 0.00 -0.00
Total Revenue		 0.00 0.00 0.00 0.01
Operating Revenue		 - - 0.00 0.01
Total Cost of Revenue		 0.00 0.00 0.00 0.01
Operating Cost of Revenue		 - - 0.00 0.01
Total Operating Expenses		 0.98 1.34 1.21 19
Selling, General & Admin Expense		 0.98 1.34 0.94 18
Marketing Expense		 - - 0.13 0.79
Research & Development Expense		 - - 0.14 0.92
Total Other Income / (Expense), net		 4.32 5.80 -0.10 -5.13
Interest Expense		 0.00 0.01 0.10 8.90
Other Income / (Expense), net		 - - 0.00 3.86
Income Tax Expense		 - - 0.00 0.00
Weighted Average Basic Shares Outstanding		 31.68M 500.97M 689.91K 1.49M
Diluted Earnings per Share		 $0.22 $0.00 ($1.90) ($16.38)
Weighted Average Diluted Shares Outstanding		 31.68M 500.97M 689.91K 1.49M
Weighted Average Basic & Diluted Shares Outstanding		 35.94M 8.99M - 5.02M

Quarterly Income Statements for Aspire Biopharma

This table shows Aspire Biopharma's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 -0.15 -0.23 -0.10 -0.22 -0.77 -16 -1.98 -1.85 -4.71 -3.22 -1.27
Consolidated Net Income / (Loss)		 -0.15 -0.23 -0.10 -0.22 -0.77 -16 -1.98 -1.85 -4.71 -3.22 -1.27
Net Income / (Loss) Continuing Operations		 -0.15 -0.23 -0.10 -0.22 -0.77 -16 -1.98 -1.85 -4.71 -3.22 -1.27
Total Pre-Tax Income 		-0.15 -0.23 -0.10 -0.22 -0.77 -16 -1.98 -1.85 -4.71 -3.22 -1.27
Total Operating Income		 -0.40 -0.23 -0.10 -0.22 -0.67 -16 -0.80 -1.15 -1.85 -1.65 -2.68
Total Gross Profit		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 -0.00 0.01 -0.03
Total Revenue		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 0.00 0.03 0.02
Operating Revenue		 - - - 0.00 - 0.00 0.00 0.00 - 0.03 0.02
Total Cost of Revenue		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 0.01 0.02 0.05
Operating Cost of Revenue		 - - - 0.00 - 0.00 0.00 0.00 - 0.02 0.05
Total Operating Expenses		 0.40 0.23 0.10 0.22 0.67 16 0.80 1.15 1.85 1.65 2.65
Selling, General & Admin Expense		 0.40 0.13 0.09 0.19 0.53 15 0.40 0.51 1.66 1.02 0.97
Marketing Expense		 - 0.09 0.00 0.02 0.02 0.22 0.05 0.43 0.09 0.33 1.22
Research & Development Expense		 - 0.01 0.01 0.01 0.12 0.26 0.35 0.21 0.10 0.30 0.23
Restructuring Charge		 - - - - - - 0.00 - - - 0.23
Total Other Income / (Expense), net		 0.25 0.00 0.00 0.00 -0.10 -0.38 -1.18 -0.70 -2.86 -1.58 1.41
Interest Expense		 - 0.00 0.00 0.00 0.10 0.29 0.89 1.48 6.23 1.83 -1.35
Interest & Investment Income		 0.26 - - - - 0.00 0.00 - - 0.01 0.06
Other Income / (Expense), net		 - 0.00 0.00 0.00 - -0.09 -0.29 0.78 3.47 0.25 -0.00
Income Tax Expense		 - - - 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Basic Earnings per Share		 ($0.33) ($0.01) $0.00 ($0.01) ($1.11) ($504.88) ($48.19) ($0.04) ($3.15) ($20.57) ($1.22)
Weighted Average Basic Shares Outstanding		 500.97M 27.60M 27.60M 27.60M 689.91K 31.58K 41.11K 49.53M 1.49M 156.69K 1.04M
Diluted Earnings per Share		 ($0.33) ($0.01) $0.00 ($0.01) ($1.11) ($504.88) ($48.19) ($0.04) ($3.15) ($20.57) ($1.22)
Weighted Average Diluted Shares Outstanding		 500.97M 27.60M 27.60M 27.60M 689.91K 31.58K 41.11K 49.53M 1.49M 156.69K 1.04M
Weighted Average Basic & Diluted Shares Outstanding		 8.99M 7.77M 7.77M 7.77M 0.00 49.53M 49.53M 107.48M 5.02M 1.30M 1.40M

Annual Cash Flow Statements for Aspire Biopharma

This table details how cash moves in and out of Aspire Biopharma's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024 2025
Period end date 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 0.50 -0.50 -0.01 1.00
Net Cash From Operating Activities		 -1.41 -0.65 -0.27 -4.92
Net Cash From Continuing Operating Activities		 -1.41 -0.65 -0.27 -4.92
Net Income / (Loss) Continuing Operations		 3.34 4.46 -1.31 -24
Consolidated Net Income / (Loss)		 3.34 4.46 -1.31 -24
Amortization Expense		 - - 0.00 8.02
Non-Cash Adjustments To Reconcile Net Income		 -4.32 -5.80 0.91 11
Changes in Operating Assets and Liabilities, net		 -0.43 0.69 0.14 0.53
Net Cash From Investing Activities		 -295 285 0.00 0.00
Net Cash From Continuing Investing Activities		 -295 285 0.00 0.00
Net Cash From Financing Activities		 297 -285 0.26 5.92
Net Cash From Continuing Financing Activities		 297 -285 0.26 5.92
Repayment of Debt		 -0.25 0.00 0.00 -3.73
Issuance of Debt		 0.00 0.16 0.00 11
Issuance of Common Equity		 297 - 0.26 0.00
Other Financing Activities, net		 - - 0.00 -0.91
Cash Interest Paid		 - - 0.00 0.04

Quarterly Cash Flow Statements for Aspire Biopharma

This table details how cash moves in and out of Aspire Biopharma's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents		 -0.00 0.04 -0.03 -0.00 -0.01 1.34 -1.14 1.74 -0.94 4.85 6.31
Net Cash From Operating Activities		 -0.16 -0.19 -0.06 -0.50 0.48 -1.75 -1.14 -1.10 -0.93 -3.04 -2.12
Net Cash From Continuing Operating Activities		 -0.16 -0.19 -0.06 -0.50 0.48 -1.75 -1.14 -1.10 -0.93 -3.04 -2.12
Net Income / (Loss) Continuing Operations		 -0.15 -0.23 -0.10 -0.22 -0.77 -16 -1.98 -1.85 -4.71 -3.22 -1.27
Consolidated Net Income / (Loss)		 -0.15 -0.23 -0.10 -0.22 -0.77 -16 -1.98 -1.85 -4.71 -3.22 -1.27
Non-Cash Adjustments To Reconcile Net Income		 -0.25 0.00 - - 0.91 15 1.18 -1.59 -3.10 0.01 -1.17
Changes in Operating Assets and Liabilities, net		 0.25 0.04 0.04 -0.28 0.34 -0.33 -0.34 0.32 0.88 -1.41 0.32
Net Cash From Financing Activities		 0.16 0.23 0.03 0.49 -0.49 3.09 - 2.85 -0.02 7.89 8.43
Net Cash From Continuing Financing Activities		 0.16 0.23 0.03 0.49 -0.49 3.09 - 2.85 -0.02 7.89 8.43
Repayment of Debt		 - 0.00 - - - 0.04 - -3.28 -0.50 -3.06 -0.57
Issuance of Common Equity		 - 0.23 0.03 - - 0.00 - - - 8.95 9.00

Annual Balance Sheets for Aspire Biopharma

This table presents Aspire Biopharma's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2021 2022 2023 2024 2025
Period end date 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 0.29 300 20 0.15 1.31
Total Current Assets		 0.29 1.10 0.13 0.15 1.31
Cash & Equivalents		 0.00 0.50 0.01 0.00 1.00
Inventories, net		 - - - 0.00 0.25
Prepaid Expenses		 0.00 0.60 0.12 0.14 0.06
Plant, Property, & Equipment, net		 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 0.00 299 20 0.00 0.00
Other Noncurrent Operating Assets		 0.00 299 20 0.00 0.00
Total Liabilities & Shareholders' Equity		 0.29 300 20 0.15 1.31
Total Liabilities		 0.29 11 0.94 1.69 7.69
Total Current Liabilities		 0.29 0.30 0.94 1.69 7.59
Short-Term Debt		 0.24 0.00 0.37 1.27 2.68
Accounts Payable		 0.00 0.18 0.32 0.31 1.01
Accrued Expenses		 0.05 - - 0.00 1.01
Other Current Liabilities		 0.00 0.12 0.24 0.11 2.89
Total Noncurrent Liabilities		 0.00 11 0.00 0.00 0.10
Other Noncurrent Operating Liabilities		 0.00 11 - 0.00 0.10
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -0.00 -9.94 -0.81 -1.54 -6.38
Total Preferred & Common Equity		 -0.00 -9.94 -0.81 -1.54 -6.38
Preferred Stock		 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -0.00 -9.94 -0.81 -1.54 -6.38
Common Stock		 0.03 0.00 12 1.24 21
Retained Earnings		 -0.03 -9.94 -13 -2.78 -27
Other Equity Adjustments		 - - - - 0.00

Quarterly Balance Sheets for Aspire Biopharma

This table presents Aspire Biopharma's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026
Total Assets		 20 20 6.87 6.66 1.97 0.99 2.40 7.12 14
Total Current Assets		 0.25 0.07 0.34 0.06 1.97 0.99 2.40 7.12 13
Cash & Equivalents		 0.00 - - - 1.35 0.21 1.95 5.86 12
Inventories, net		 - - - - - - 0.04 0.37 0.29
Prepaid Expenses		 0.25 0.07 0.04 0.04 0.62 0.78 0.42 0.89 1.01
Plant, Property, & Equipment, net		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 20 20 6.52 6.60 0.00 0.00 0.00 0.00 0.08
Other Noncurrent Operating Assets		 20 20 6.52 6.60 0.00 0.00 0.00 0.00 0.08
Total Liabilities & Shareholders' Equity		 20 20 6.87 6.66 1.97 0.99 2.40 7.12 14
Total Liabilities		 0.32 2.63 6.24 6.57 9.92 11 14 3.25 1.78
Total Current Liabilities		 0.32 2.63 6.24 6.57 9.87 11 14 3.15 1.69
Short-Term Debt		 - 0.22 0.43 0.44 4.89 5.45 6.12 0.50 0.00
Accounts Payable		 0.10 0.37 0.58 0.90 1.43 1.35 1.06 0.86 0.97
Accrued Expenses		 - - - - 0.32 0.38 0.27 0.44 0.71
Other Current Liabilities		 0.21 2.05 5.23 5.23 3.23 3.38 6.41 1.35 0.00
Total Noncurrent Liabilities		 0.00 0.00 0.00 0.00 0.05 0.05 0.01 0.10 0.10
Other Noncurrent Operating Liabilities		 0.00 - - - 0.05 0.05 0.01 0.10 0.10
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -0.06 -2.57 -5.90 -6.51 -7.95 -9.62 -11 3.87 12
Total Preferred & Common Equity		 -0.06 -2.57 -5.90 -6.51 -7.95 -9.62 -11 3.87 12
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -0.06 -2.57 -5.90 -6.51 -7.95 -9.62 -11 3.87 12
Common Stock		 11 11 8.86 8.86 11 11 11 34 44
Retained Earnings		 -11 -14 -15 -15 -19 -21 -23 -30 -32
Other Equity Adjustments		 - - - - - - - 0.00 0.00

Annual Metrics And Ratios for Aspire Biopharma

This table displays calculated financial ratios and metrics derived from Aspire Biopharma's official financial filings.

Metric 2022 2023 2024 2025
Period end date 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 35,937,500.00 8,991,229.00 7,765,144.00 214,954,356.00
DEI Adjusted Shares Outstanding		 898,438.00 224,781.00 6,471.00 179,129.00
DEI Earnings Per Adjusted Shares Outstanding		 3.72 19.86 -202.42 -136.67
Growth Metrics		 - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% -37.26% 9.65% -516.99%
EBIT Growth		 0.00% -37.26% 9.65% -1,179.28%
NOPAT Growth		 0.00% -37.26% 36.75% -1,498.13%
Net Income Growth		 0.00% 33.65% -129.34% -1,768.95%
EPS Growth		 0.00% -100.00% -129.34% -1,768.95%
Operating Cash Flow Growth		 0.00% 53.64% 59.40% -1,756.62%
Free Cash Flow Firm Growth		 0.00% 0.00% -92.95% -148.29%
Invested Capital Growth		 0.00% -93.26% -101.42% -1,599.23%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 219.53%
EBITDA Q/Q Growth		 0.00% -7.08% -28.03% 64.86%
EBIT Q/Q Growth		 0.00% -7.08% -28.03% 27.13%
NOPAT Q/Q Growth		 0.00% -7.08% -28.03% 8.97%
Net Income Q/Q Growth		 0.00% -34.78% -88.45% -2.14%
EPS Q/Q Growth		 0.00% -100.00% -88.45% -2.14%
Operating Cash Flow Q/Q Growth		 0.00% -22.57% 70.56% 7.20%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 2.68% -29.09%
Invested Capital Q/Q Growth		 0.00% -0.63% -152.58% 35.47%
Profitability Metrics		 - - - -
Gross Margin		 0.00% 0.00% 0.00% -1.87%
EBITDA Margin		 0.00% 0.00% 0.00% -120,460.40%
Operating Margin		 0.00% 0.00% 0.00% -312,016.95%
EBIT Margin		 0.00% 0.00% 0.00% -249,764.62%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% -394,725.06%
Tax Burden Percent		 100.00% 100.00% 100.08% 100.00%
Interest Burden Percent		 -342.12% -333.10% 108.09% 158.04%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 2.31% 2.90% -14.93% 618.48%
Cash Return on Invested Capital (CROIC)		 0.00% 173.87% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% -2,121.75%
Return on Assets (ROA)		 0.00% 0.00% 0.00% -3,353.18%
Return on Common Equity (ROCE)		 -0.08% -0.10% 2.00% 618.48%
Return on Equity Simple (ROE_SIMPLE)		 -33.61% -551.14% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -0.98 -1.34 -0.85 -14
NOPAT Margin		 0.00% 0.00% 0.00% -218,411.86%
Net Nonoperating Expense Percent (NNEP)		 868.08% 8,572.66% 56.89% 745.26%
Return On Investment Capital (ROIC_SIMPLE)		 - 306.71% 310.19% 366.00%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 101.87%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 284,382.97%
R&D to Revenue		 0.00% 0.00% 0.00% 14,897.03%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 312,015.08%
Earnings before Interest and Taxes (EBIT)		 -0.98 -1.34 -1.21 -15
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -0.98 -1.34 -1.21 -7.47
Valuation Ratios		 - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 0.00 0.00 0.00 2,285.75
Price to Earnings (P/E)		 110.82 21.93 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.90% 4.56% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 2.32 6.08 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 2,555.24
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.44 4.80 0.00
Leverage & Solvency		 - - - -
Debt to Equity		 0.00 0.02 -0.82 -0.42
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00
Financial Leverage		 0.00 0.00 0.09 -0.37
Leverage Ratio		 1.04 1.04 1.15 -0.18
Compound Leverage Factor		 -3.56 -3.46 1.24 -0.29
Debt to Total Capital		 0.00% 1.92% -463.61% -72.28%
Short-Term Debt to Total Capital		 0.00% 1.92% -463.61% -72.28%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 103.44% 102.24% 0.00% 0.00%
Common Equity to Total Capital		 -3.44% -4.16% 563.61% 172.28%
Debt to EBITDA		 0.00 -0.28 -1.05 -0.36
Net Debt to EBITDA		 0.00 -0.27 -1.04 -0.22
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 -0.28 -1.49 -0.20
Net Debt to NOPAT		 0.00 -0.27 -1.49 -0.12
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00
Altman Z-Score		 19.93 61.51 -34.02 -72.67
Noncontrolling Interest Sharing Ratio		 103.44% 103.49% 113.39% 0.00%
Liquidity Ratios		 - - - -
Current Ratio		 3.62 0.14 0.09 0.17
Quick Ratio		 1.64 0.01 0.00 0.13
Cash Flow Metrics		 - - - -
Free Cash Flow to Firm (FCFF)		 0.00 268 19 -9.12
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 29,865.68 192.70 -1.03
Operating Cash Flow to Interest Expense		 0.00 -72.84 -2.71 -0.55
Operating Cash Flow Less CapEx to Interest Expense		 0.00 -72.84 -2.71 -0.55
Efficiency Ratios		 - - - -
Asset Turnover		 0.00 0.00 0.00 0.01
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.01
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 38,261.91
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 -38,261.91
Capital & Investment Metrics		 - - - -
Invested Capital		 289 19 -0.28 -4.70
Invested Capital Turnover		 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 -269 -20 -4.43
Enterprise Value (EV)		 669 118 91 16
Market Capitalization		 370 98 89 14
Book Value per Share		 ($0.28) ($0.09) ($0.20) ($0.06)
Tangible Book Value per Share		 ($0.28) ($0.09) ($0.20) ($0.06)
Total Capital		 289 19 -0.27 -3.70
Total Debt		 0.00 0.37 1.27 2.68
Total Long-Term Debt		 0.00 0.00 0.00 0.00
Net Debt		 -0.50 0.36 1.26 1.67
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.30 -0.45 -0.28 -4.61
Debt-free Net Working Capital (DFNWC)		 0.79 -0.44 -0.27 -3.61
Net Working Capital (NWC)		 0.79 -0.81 -1.54 -6.28
Net Nonoperating Expense (NNE)		 -4.32 -5.80 0.46 11
Net Nonoperating Obligations (NNO)		 -0.50 0.36 1.26 1.67
Total Depreciation and Amortization (D&A)		 0.00 0.00 0.00 8.02
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% -74,319.85%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% -58,133.07%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% -101,268.41%
Earnings Adjustments		 - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.46 ($1,827.60) $0.00
Adjusted Weighted Average Basic Shares Outstanding		 31.68M 19.18M 429.67K 49.83K
Adjusted Diluted Earnings per Share		 $0.00 $0.46 ($1,827.60) ($491.40)
Adjusted Weighted Average Diluted Shares Outstanding		 31.68M 19.18M 429.67K 49.83K
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 35.94M 8.99M 0.00 167.47K
Normalized Net Operating Profit after Tax (NOPAT)		 -0.68 -0.94 -0.85 -14
Normalized NOPAT Margin		 0.00% 0.00% 0.00% -218,411.86%
Pre Tax Income Margin		 0.00% 0.00% 0.00% -394,725.06%
Debt Service Ratios		 - - - -
EBIT to Interest Expense		 0.00 -149.47 -12.36 -1.74
NOPAT to Interest Expense		 0.00 -149.47 -8.65 -1.52
EBIT Less CapEx to Interest Expense		 0.00 -149.47 -12.36 -1.74
NOPAT Less CapEx to Interest Expense		 0.00 -149.47 -8.65 -1.52
Payout Ratios		 - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 8.94% 6,382.42% 0.00% 0.00%

Quarterly Metrics And Ratios for Aspire Biopharma

This table displays calculated financial ratios and metrics derived from Aspire Biopharma's official financial filings.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding		 8,991,229.00 8,991,229.00 7,765,144.00 7,765,144.00 7,765,144.00 7,765,144.00 99,051,940.00 49,525,970.00 214,954,356.00 10,048,248.00 1,295,234.00
DEI Adjusted Shares Outstanding		 224,781.00 224,781.00 194,129.00 194,129.00 6,471.00 6,471.00 2,476,299.00 1,238,149.00 179,129.00 334,942.00 1,295,234.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.67 -1.03 -0.50 -1.11 -118.33 -2,463.50 -0.80 -1.49 -26.28 -9.62 -0.98
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -28.21% 28.84% 66.37% 33.71% -65.85% -6,676.38% -1,023.87% -72.09% 1,241.04% 101.21% -145.89%
EBIT Growth		 -28.21% 28.84% 66.37% 33.71% -65.85% -6,676.38% -1,023.87% -72.09% 342.72% 91.09% -145.89%
NOPAT Growth		 10.25% 50.19% 76.46% 33.71% -65.85% -6,635.28% -725.28% -432.16% -176.98% 89.42% -234.82%
Net Income Growth		 -106.77% -108.04% -105.35% -212.27% -407.39% -6,801.90% -1,944.19% -755.64% -514.82% 79.78% 35.99%
EPS Growth		 -306.25% -106.25% -100.00% 0.00% -407.39% -6,801.90% 0.00% -300.00% -514.82% 79.78% 97.47%
Operating Cash Flow Growth		 -335.26% -5.97% 70.39% -296.68% 407.16% -807.66% -1,927.43% -122.75% -293.47% -73.48% -85.54%
Free Cash Flow Firm Growth		 0.00% 4,050.28% -92.81% -92.91% -92.83% -95.87% -74.41% -62.88% -83.73% -136.04% -219.92%
Invested Capital Growth		 -93.26% -93.90% -94.77% -97.31% -101.42% -124.81% -514.65% -1,484.59% -1,599.23% 66.25% 90.64%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 119.53% 565.41% -26.88%
EBITDA Q/Q Growth		 -23.98% 42.63% 58.04% -122.09% -210.20% -2,244.00% 93.04% 65.99% 2,156.76% -97.51% -1,513.25%
EBIT Q/Q Growth		 -23.98% 42.63% 58.04% -122.09% -210.20% -2,244.00% 93.04% 65.99% 537.52% -186.03% -92.09%
NOPAT Q/Q Growth		 -23.98% 42.63% 58.04% -122.09% -210.20% -2,229.78% 94.86% -43.21% -61.45% 10.99% -62.69%
Net Income Q/Q Growth		 -117.90% -53.05% 58.04% -123.13% -254.05% -1,981.90% 87.57% 6.60% -154.40% 31.54% 60.65%
EPS Q/Q Growth		 -3,200.00% 96.97% 100.00% 0.00% -254.05% -1,981.90% 90.48% 0.00% -154.40% 31.54% 94.07%
Operating Cash Flow Q/Q Growth		 -24.98% -23.60% 70.85% -781.05% 196.78% -465.23% 34.90% 3.20% 15.94% -227.48% 30.37%
Free Cash Flow Firm Q/Q Growth		 0.88% 1.80% -93.05% -0.69% 1.92% -41.29% -52.76% 44.05% -55.33% -230.09% -43.28%
Invested Capital Q/Q Growth		 -0.63% -8.57% -94.07% -50.09% -152.58% -1,493.91% -28.17% -66.65% 35.47% 68.35% 72.52%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 45.54% -23.47% 20.28% -145.12%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -19,084.75% 178,806.85% 668.46% -12,919.63%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -59,015.82% -43,403.52% -5,805.98% -12,918.30%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -19,084.75% 38,036.17% -4,917.86% -12,919.63%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -95,337.09% -110,484.25% -11,367.02% -6,116.83%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.47% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 37.48% 100.00% 100.00% 100.00% 114.68% 101.85% 181.89% 499.55% -290.47% 231.14% 47.35%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 2.90% 0.88% -5.24% -7.07% -14.93% -354.02% 496.90% 421.35% 618.48% 575.98% -1,032.14%
Cash Return on Invested Capital (CROIC)		 173.87% 176.20% 173.14% 182.94% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -8.17% 323.12% -37.42% -98.32%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -40.82% -938.56% -86.49% -46.55%
Return on Common Equity (ROCE)		 -0.10% -0.04% 1.41% 2.36% 2.00% 387.34% 857.55% 665.83% 618.48% 575.98% -1,032.14%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -0.28 -0.16 -0.07 -0.15 -0.47 -11 -0.56 -0.80 -1.29 -1.15 -1.87
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -41,311.07% -30,382.46% -4,064.18% -9,042.81%
Net Nonoperating Expense Percent (NNEP)		 193.36% -141.53% 19.22% 30.09% 36.71% 268.96% 50.14% 45.47% 232.62% -227.73% 17.52%
Return On Investment Capital (ROIC_SIMPLE)		 64.50% 6.88% 1.24% 2.48% 171.05% 355.07% 13.43% 15.01% 34.98% -26.38% -15.94%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 54.46% 123.47% 79.72% 245.12%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 26,429.31% 38,845.32% 3,599.11% 4,679.78%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 10,710.92% 2,347.69% 1,046.53% 1,126.19%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 59,061.36% 43,380.05% 5,826.26% 12,773.18%
Earnings before Interest and Taxes (EBIT)		 -0.40 -0.23 -0.10 -0.22 -0.67 -16 -1.09 -0.37 1.62 -1.39 -2.68
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -0.40 -0.23 -0.10 -0.22 -0.67 -16 -1.09 -0.37 7.62 0.19 -2.68
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.34 0.59
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.34 0.59
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 5,256.23 2,285.75 149.76 125.10
Price to Earnings (P/E)		 21.93 72.79 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 4.56% 1.37% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 6.08 6.71 89.53 193.42 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 7,407.95 2,555.24 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.44 0.44 5.15 5.54 4.80 0.76 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.02 0.01 0.68 4.83 -0.82 -0.61 -0.57 -0.53 -0.42 0.13 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 0.00 0.00 0.01 0.02 0.09 0.39 -0.63 -0.41 -0.37 0.45 -3.23
Leverage Ratio		 1.04 1.04 1.31 1.35 1.15 2.31 -0.87 -0.80 -0.18 -2.22 6.79
Compound Leverage Factor		 0.39 1.04 1.31 1.35 1.32 2.35 -1.59 -3.98 0.54 -5.14 3.21
Debt to Total Capital		 1.92% 1.22% 40.55% 82.85% -463.61% -159.31% -130.69% -114.64% -72.28% 11.43% 0.00%
Short-Term Debt to Total Capital		 1.92% 1.22% 40.55% 82.85% -463.61% -159.31% -130.69% -114.64% -72.28% 11.43% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 102.24% 113.22% 618.39% 1,253.65% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 -4.16% -14.44% -558.94% -1,236.51% 563.61% 259.31% 230.69% 214.64% 172.28% 88.57% 100.00%
Debt to EBITDA		 -0.28 -0.17 -0.41 -0.46 -1.05 -0.29 -0.27 -0.29 -0.36 0.06 0.00
Net Debt to EBITDA		 -0.27 -0.17 -0.41 -0.46 -1.04 -0.21 -0.26 -0.20 -0.22 -0.64 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 -0.28 -0.17 -0.58 -0.66 -1.49 -0.42 -0.38 -0.41 -0.20 -0.13 0.00
Net Debt to NOPAT		 -0.27 -0.17 -0.58 -0.66 -1.49 -0.31 -0.37 -0.28 -0.12 1.41 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 61.67 21.41 4.33 4.15 -21.91 -44.16 -43.77 -18.93 -29.64 -5.01 -0.56
Noncontrolling Interest Sharing Ratio		 103.49% 104.15% 126.96% 133.43% 113.39% 209.41% -72.58% -58.02% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 0.14 0.02 0.06 0.01 0.09 0.20 0.09 0.17 0.17 2.26 7.99
Quick Ratio		 0.01 0.00 0.05 0.00 0.00 0.14 0.02 0.14 0.13 1.86 7.22
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 269 274 19 19 19 11 4.87 7.02 3.13 -4.08 -5.84
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 196.58 39.01 5.46 4.74 0.50 -2.22 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 4.89 -6.04 -1.28 -0.75 -0.15 -1.66 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 4.89 -6.04 -1.28 -0.75 -0.15 -1.66 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.01 0.01
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.03 0.07
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 339,200.68 38,261.91 14,450.26 5,318.40
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -339,200.68 -38,261.91 -14,450.26 -5,318.40
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 19 18 1.06 0.53 -0.28 -4.41 -4.37 -7.29 -4.70 -1.49 -0.41
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.01 -0.02
Increase / (Decrease) in Invested Capital		 -269 -274 -19 -19 -20 -22 -5.43 -7.82 -4.43 2.92 3.97
Enterprise Value (EV)		 118 119 94 102 91 8.06 19 14 16 -0.18 -5.25
Market Capitalization		 98 99 88 95 89 4.52 13 10 14 5.17 6.92
Book Value per Share		 ($0.09) ($0.29) ($0.76) ($0.84) ($0.20) ($1.02) ($0.19) ($0.23) ($0.06) $0.77 $9.08
Tangible Book Value per Share		 ($0.09) ($0.29) ($0.76) ($0.84) ($0.20) ($1.02) ($0.19) ($0.23) ($0.06) $0.77 $9.08
Total Capital		 19 18 1.06 0.53 -0.27 -3.07 -4.17 -5.34 -3.70 4.37 12
Total Debt		 0.37 0.22 0.43 0.44 1.27 4.89 5.45 6.12 2.68 0.50 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 0.36 0.22 0.43 0.44 1.26 3.54 5.24 4.18 1.67 -5.36 -12
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.45 -2.35 -5.47 -6.07 -0.28 -4.36 -4.33 -7.28 -4.61 -1.39 -0.39
Debt-free Net Working Capital (DFNWC)		 -0.44 -2.35 -5.47 -6.07 -0.27 -3.02 -4.12 -5.33 -3.61 4.46 12
Net Working Capital (NWC)		 -0.81 -2.57 -5.90 -6.51 -1.54 -7.90 -9.57 -11 -6.28 3.96 12
Net Nonoperating Expense (NNE)		 -0.13 0.07 0.03 0.07 0.30 5.05 1.42 1.05 3.41 2.07 -0.61
Net Nonoperating Obligations (NNO)		 0.36 0.22 0.43 0.44 1.26 3.54 5.24 4.18 1.67 -5.36 -12
Total Depreciation and Amortization (D&A)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 6.00 1.58 0.00
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -375,111.03% -74,319.85% -4,031.53% -701.41%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -274,736.42% -58,133.07% 12,918.33% 21,305.82%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -590,282.17% -101,268.41% 11,473.64% 21,305.82%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.33) ($0.27) ($0.07) ($0.07) ($1,332.00) $0.00 ($0.04) ($0.04) ($3,780.00) ($20.57) ($1.22)
Adjusted Weighted Average Basic Shares Outstanding		 500.97M 8.99M 8.47M 7.77M 575.00 0.00 49.33M 49.53M 1.25K 156.69K 1.04M
Adjusted Diluted Earnings per Share		 ($0.33) ($0.27) ($0.07) ($0.07) ($1,332.00) $0.00 ($0.04) ($0.04) ($3,780.00) ($20.57) ($1.22)
Adjusted Weighted Average Diluted Shares Outstanding		 500.97M 8.99M 8.47M 7.77M 575.00 0.00 49.33M 49.53M 1.25K 156.69K 1.04M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 ($1,332.00) $0.00 $0.00 $0.00 ($3,780.00) $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 8.99M 7.77M 7.77M 7.77M 0.00 0.00 49.53M 107.48M 4.19K 1.30M 1.40M
Normalized Net Operating Profit after Tax (NOPAT)		 -0.28 -0.16 -0.07 -0.15 -0.47 -11 -0.56 -0.80 -1.29 -1.15 -1.71
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -41,311.07% -30,382.46% -4,064.18% -8,268.20%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -95,337.09% -110,484.25% -11,367.02% -6,116.83%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 -6.81 -53.98 -1.22 -0.25 0.26 -0.76 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 -4.77 -37.56 -0.63 -0.54 -0.21 -0.63 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 -6.81 -53.98 -1.22 -0.25 0.26 -0.76 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 -4.77 -37.56 -0.63 -0.54 -0.21 -0.63 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 6,382.42% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Aspire Biopharma’s Q2 2026 results show improving liquidity, but the company remains loss-making and dependent on external financing. Revenue declined to $20,732 from $28,353 in Q1 2026, although the company has now reported revenue in each of the first two quarters of 2026 after generating only minimal revenue during 2025. Gross profit was negative $30,086 in Q2, compared with positive gross profit of $5,750 in Q1, indicating that the current revenue base is not yet sufficient to cover product costs.

The net loss narrowed substantially to $1.27 million in Q2 from $3.22 million in Q1 and $4.71 million in Q4 2025. However, operating expenses increased to $2.65 million, led by $1.22 million of marketing expense, $970,211 of selling, general and administrative expense, and a $229,418 restructuring charge. Operating cash flow remained negative at $2.12 million, although this was an improvement from the $3.04 million outflow in Q1.

Liquidity improved sharply during the quarter. Cash and equivalents rose from $5.86 million at March 31, 2026, to $12.17 million at June 30, supported primarily by a $9.0 million common-equity issuance. Aspire also repaid $574,214 of debt. Based on the Q2 operating cash burn, the cash balance appears to provide several months of funding, but this estimate could change materially as marketing, research and development, and commercialization expenses fluctuate.

The balance sheet is stronger than it was during 2025. Total liabilities declined from $13.87 million in Q3 2025 to $1.78 million in Q2 2026, while total equity improved from negative $11.47 million to positive $11.76 million. Current assets of $13.47 million substantially exceeded current liabilities of $1.69 million at quarter-end. Nevertheless, retained earnings remained negative at $31.75 million, reflecting the company’s accumulated losses.

  • Liquidity improved: Cash increased to $12.17 million in Q2 2026 from $5.86 million in Q1 and only $1.95 million in Q3 2025.
  • Net losses are narrowing: The Q2 loss of $1.27 million was significantly lower than the $3.22 million loss in Q1 2026 and the $4.71 million loss in Q4 2025.
  • Operating cash burn improved: Cash used in operating activities declined to $2.12 million in Q2 from $3.04 million in Q1 and $3.10 million in Q2 2025.
  • Balance-sheet recovery: Total equity was positive at $11.76 million in Q2 2026, reversing the negative equity reported throughout the provided 2024 and 2025 periods.
  • Lower reported liabilities: Total liabilities fell to $1.78 million from $3.25 million in Q1 2026 and $13.87 million in Q3 2025.
  • Early revenue generation: Q2 revenue of $20,732 followed $28,353 in Q1, but the amounts remain too small to demonstrate a stable commercial revenue trend.
  • Financing dependence: Q2 financing produced $8.43 million of net cash, primarily from issuing common equity, rather than from internally generated cash.
  • Gross profitability deteriorated: Q2 cost of revenue exceeded revenue, producing a $30,086 gross loss after a $5,750 gross profit in Q1.
  • Operating expenses remain high: Marketing and SG&A totaled approximately $2.19 million in Q2, far exceeding revenue, while a restructuring charge added further pressure.
  • Dilution and reporting volatility remain risks: Common-equity issuances have been a major source of funding, and reported weighted-average shares have varied substantially across periods. Investors should also account for restated 2024 and 2025 statements when comparing historical results.
11/13/26 08:01 PM ETAI Generated. May Contain Errors.

Aspire Biopharma Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Aspire Biopharma's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Aspire Biopharma's net income appears to be on a downward trend, with a most recent value of -$24.48 million in 2025, compared with $3.34 million in 2022. The previous period was -$1.31 million in 2024. See where experts think Aspire Biopharma is headed by visiting Aspire Biopharma's forecast page.

Aspire Biopharma's total operating income in 2025 was -$19.35 million, based on the following breakdown:
  • Total Gross Profit: -$116.00
  • Total Operating Expenses: $19.35 million

Over the last 3 years, Aspire Biopharma's total revenue changed from $0.00 in 2022 to $6.20 thousand in 2025, a change of 620,200.0%.

In the past 11 quarters, Aspire Biopharma's cash and equivalents has ranged from $0.00 in Q1 2024 to $12.17 million in Q2 2026, and is currently $12.17 million as of their latest financial filing in Q2 2026.

Aspire Biopharma had total debt of $2.68 million at the end of 2025, a 111.2% increase from 2024, and none in 2022.

Over the last 3 years, Aspire Biopharma's book value per share changed from -0.28 in 2022 to -0.06 in 2025, a change of 78.6%.


Related Companies

Financial statements for NASDAQ:ASBP last updated on 8/14/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Trump’s EO to send this $5 stock ripping higher…?
President Trump's December executive order declared space a national security and economic priority, fueling a...
Traders Agency | Sponsoredtc pixel
Today's free pick (on me)
Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...
Behind the Markets | Sponsoredtc pixel
Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...
Weiss Ratings | Sponsoredtc pixel
Your free book is about to disappear
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
The investigation Porter spent tens of thousands to document
Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...
Porter & Company | Sponsoredtc pixel
Why I'm selling my Snapback Indicator for just $7
For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...
Base Camp Trading | Sponsoredtc pixel
Uranium Mine Flood That Sparked a 2006 Price Surge Returns
In 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...
Digest Publishing | Sponsoredtc pixel
URGENT: If you own a home, please review the map below.
More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...
Paradigm Press | Sponsoredtc pixel